US20050112657A1 - Methods and compositions for multiplex amplification of nucleic acids - Google Patents

Methods and compositions for multiplex amplification of nucleic acids Download PDF

Info

Publication number
US20050112657A1
US20050112657A1 US10/975,361 US97536104A US2005112657A1 US 20050112657 A1 US20050112657 A1 US 20050112657A1 US 97536104 A US97536104 A US 97536104A US 2005112657 A1 US2005112657 A1 US 2005112657A1
Authority
US
United States
Prior art keywords
exon
primers
amplicon
pcr
exons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/975,361
Inventor
Haiime Matsuzaki
Eric Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymetrix Inc
Original Assignee
Affymetrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymetrix Inc filed Critical Affymetrix Inc
Priority to US10/975,361 priority Critical patent/US20050112657A1/en
Publication of US20050112657A1 publication Critical patent/US20050112657A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Definitions

  • PCR polymerase chain reaction
  • PCR Polymerase chain reaction
  • PCR can be used to amplify genomic DNA or other sources of nucleic acids for analysis. It is often desirable to be able to achieve equimolar yields of different length amplicons when performing multiplex PCR or multiple PCR reactions. Having an approximately equimolar yield of amplicons is particularly useful, for example, when approximately equal representation of certain regions of genomic DNA amplified after multiplex PCR is desired. Prior to the methods of present invention, finding the appropriate experimental conditions useful to achieve this result has been difficult because PCR amplifies nucleic acids having different lengths with different efficiencies. The yield of longer amplicons is often less than the yield of shorter amplicons because of those differences in PCR amplification efficiency.
  • a method of performing multiple polymerase chain reactions in a single vessel comprises the steps of priming DNA synthesis on a template in a vessel with at least two sets of primers.
  • C A is the concentration of primers for an amplicon A.
  • C L is the concentration of primer for the longest amplicon.
  • L A is the length of the amplicon A.
  • L L is the length of the longest amplicon.
  • Another embodiment provided by the invention is a method of performing multiple polymerase chain reactions in a single vessel.
  • the method comprises priming DNA synthesis on a genomic p53 template in a vessel with ten sets of primers which amplify exons 2-11 of p53.
  • the primers are shown in SEQ ID NO: ID NOS: 1-20.
  • the primers are present in the vessel at the following ratio: exon 2 (89.4): exon 3 (26.9): exon 4 (450): exon 5 (245.8): exon 6 ( ⁇ 138.3): exon 7 (101.8): exon 8 (193.0): exon 9 (70.8): exon 10 (146.5): exon 11 (177.3).
  • a set of primers for performing multiple polymerase chain reactions in a single vessel comprises twenty primers having sequences as shown in SEQ ID NO: 1-20.
  • a mixture of primers for performing multiplex polymerase chain reaction is provided.
  • the primers are present in the mixture at a predetermined ratio to each other.
  • the present invention thus provides the art with a method useful for performing multiplex PCR This method is particularly useful for amplification of multiple exons of p53. Moreover, a particular primer set useful for performing such multiplex PCR is also provided.
  • FIG. 1 shows the difference in yields that one might expect, for example, when starting with equal primer concentrations used to amplify amplicons of varying lengths: A, B, C.
  • FIG. 2 illustrates the relationship for given values X and L L , using the amplicons from different exons of the human p53 gene as an example.
  • This relationship can be placed in a computer readable medium or be used with a computer system if desired.
  • FIG. 2 illustrates the relationship for given values X and L L , using the amplicons from different exons of the human p53 gene as an example.
  • primer concentrations as set forth, for example in FIG. 2
  • one skilled in the art can determine the optimum set of primer concentrations to yield approximately equimolar yields of varying length amplicons in a multiplex or multiple PCR.
  • primers having both comparable base composition and comparable melting temperatures are used.
  • Mg +2 concentration, annealing temperatures, and cycling times of the PCR are optimized prior to choosing the desired set of primer concentrations in accordance with the present invention.
  • PCR techniques applicable to the present invention include inter alia those discussed in PCR PRIMR: A L ABORATORY M tract , Dieffenbac, C. W. and Dveksler, G. S., eds., Cold Spring Harbor Laboratory Press (1995).
  • the present application further provides primer sequences, primer concentrations, and experimental conditions useful in the amplification of the coding region of the human p53 gene.
  • Particularly useful primers for amplification of exons of the p53 gene are set forth in Table 1.
  • Table 2 shows particularly useful concentrations of the primers set forth in Table 1 for multiplex PCR amplification using the experimental conditions set forth in Table 3.
  • Table 2 shows particularly useful concentrations of the primers set forth in Table 1 for multiplex PCR amplification using the experimental conditions set forth in Table 3.
  • TABLE 2 Primer Concentrations in p53 Primer Set Amplicon Length Primer Concs Longest 4 368 bp 450.0 nM 5 272 bp 245.8 nM 8 241 bp 193.0 nM 11 231 bp 177.3 nM 10 210 bp 146.5 nM 6 204 bp 138.3 nM 7 175 bp 101.8 nM 2 164 bp 89.4 nM 9 146 bp 70.8 nM Shortest 3 90 bp 26.9 nM Values of X 2 Typical values of C L 450 nM
  • the methods and compositions of the present invention are useful in virtually any context in which equimolar yields of various PCR products are desired. Such contexts include without limitation paternity testing, forensic analysis, genetic screening, polymorphism detection, and mutation analyses.
  • the present invention can be used to amplify nucleic acids for all forms of sequence analysis known to those skilled in the art. Sequence analysis techniques includes, for example, dideoxy-sequencing and sequence analysis using high-density nucleic acid arrays: the GeneChip® probe arrays or VLSIPSTM technology of Affymetrix, Inc. High density nucleic acid arrays are discussed for example in Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X.

Abstract

A method is described for predetermining ratios of primer pairs present in a single reaction vessel so as to achieve approximately equimolar yield of products. The ratios are determined as a function of the length of the amplicon and the length of other amplicons being simultaneously tested. The primers may desirably be for p53 gene sequences.

Description

    RELATED APPLICATION
  • This application claims priority to U.S. Provisional Application Ser. No. 60/050,405, filed on Jun. 20, 1997, the text of which is expressly incorporated herein.
    • BACKGROUND OF THE INVENTION
  • The polymerase chain reaction (PCR) is a simple and versatile method to amplify in vitro a specific segment of DNA for subsequent study (Saiki et al., Science 230:1350 (1985); Saiki et al., Science 235:487 (1985)). The PCR method has gained widespread use in biomedical research, and has revolutionized the accurate and early diagnosis of many inherited and acquired genetic disorders (Eisenstein, N. Engl. J. Med. 322:178 (1990)), particularly those caused by point mutations or small insertions or deletions including sickle cell anemia (Saiki et al., Science 230:1350 (1985)), hemophilia A (Kogan et al., N. Engl. J. Med. 317:985 (1987)), Tay-Sach's disease (Myerowitz, Proc. Natl. Acad. Sci. USA 85:3955 (1988); Myerowitz et al., J. Biol. Chem. 263:18587 (1988)), cystic fibrosis (Riordan et al., Science 245:1066 (1989)), and many others. With PCR, it is also possible to detect heterozygotic carriers in recessive disorders.
  • Polymerase chain reaction (PCR) is used for a variety of purposes. PCR can be used to amplify genomic DNA or other sources of nucleic acids for analysis. It is often desirable to be able to achieve equimolar yields of different length amplicons when performing multiplex PCR or multiple PCR reactions. Having an approximately equimolar yield of amplicons is particularly useful, for example, when approximately equal representation of certain regions of genomic DNA amplified after multiplex PCR is desired. Prior to the methods of present invention, finding the appropriate experimental conditions useful to achieve this result has been difficult because PCR amplifies nucleic acids having different lengths with different efficiencies. The yield of longer amplicons is often less than the yield of shorter amplicons because of those differences in PCR amplification efficiency. FIG. 1 shows the difference in yields that one might expect, for example, when starting with equal primer concentrations used to amplify amplicons of varying lengths: A, B, C. There is a continuing need in the art for methods which permit the amplification of different sequences with the same efficiency so that approximately equimolar products result.
  • It is an object of the present invention to provide a method of performing multiplex PCR which achieve approximately equimolar products.
  • It is another object of the invention to provide a set of primers for amplification of p53.
  • It is yet another object of the invention to provide a set of primers for amplification of p53 to achieve approximately equimolar products.
  • It is still another object of the invention to provide a mixture of primers for performing multiplex PCR.
  • These and other objects of the invention are provided by one or more of the embodiments provided below. In one embodiment of the invention a method of performing multiple polymerase chain reactions in a single vessel is provided. The method comprises the steps of priming DNA synthesis on a template in a vessel with at least two sets of primers. The primers are present in the vessel at a predetermined ratio which is described by the formula:
    C A =C L(L A ÷L L)2
    CA is the concentration of primers for an amplicon A. CL is the concentration of primer for the longest amplicon. LA is the length of the amplicon A. LL is the length of the longest amplicon.
  • Another embodiment provided by the invention is a method of performing multiple polymerase chain reactions in a single vessel. The method comprises priming DNA synthesis on a genomic p53 template in a vessel with ten sets of primers which amplify exons 2-11 of p53. The primers are shown in SEQ ID NO: ID NOS: 1-20. The primers are present in the vessel at the following ratio: exon 2 (89.4): exon 3 (26.9): exon 4 (450): exon 5 (245.8): exon 6 (−138.3): exon 7 (101.8): exon 8 (193.0): exon 9 (70.8): exon 10 (146.5): exon 11 (177.3).
  • According to still another embodiment of the invention a set of primers for performing multiple polymerase chain reactions in a single vessel is provided. The set comprises twenty primers having sequences as shown in SEQ ID NO: 1-20.
  • According to yet another embodiment of the invention a mixture of primers for performing multiplex polymerase chain reaction is provided. The primers are present in the mixture at a predetermined ratio to each other. The ratio of the concentrations of the primers is described by:
    C A =C L(L A ÷L L)
    wherein CA is the concentration of primers for an amplicon A; wherein CL is the concentration of primer for the longest amplicon; wherein LA is the length of the amplicon A; and wherein LL is the length of the longest amplicon.
  • The present invention thus provides the art with a method useful for performing multiplex PCR This method is particularly useful for amplification of multiple exons of p53. Moreover, a particular primer set useful for performing such multiplex PCR is also provided.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the difference in yields that one might expect, for example, when starting with equal primer concentrations used to amplify amplicons of varying lengths: A, B, C.
  • FIG. 2 illustrates the relationship for given values X and LL, using the amplicons from different exons of the human p53 gene as an example.
    • DETAILED DESCRIPTION OF THE INVENTION
  • It is a discovery of the present invention that approximately equimolar yields of amplicons of varying lengths can be easily produced by multiplex PCR It has been determined that varying the primer concentrations as a function of the lengths of amplicons yields approximately equimolar amounts of amplicons of varying lengths. The relationship between primer concentration and the length of amplicons is as follows:
    C A =C L(L A /L L)X
    wherein
      • CA=the concentration of primers for an amplicon A;
      • CL=the concentration of primer for the longest amplicon;
      • LA=the length of amplicon A;
      • LL=the length of the longest amplicon; and
      • X is usually not zero and is often between one and three.
  • This relationship can be placed in a computer readable medium or be used with a computer system if desired.
  • FIG. 2 illustrates the relationship for given values X and LL, using the amplicons from different exons of the human p53 gene as an example. Using primer concentrations as set forth, for example in FIG. 2, one skilled in the art can determine the optimum set of primer concentrations to yield approximately equimolar yields of varying length amplicons in a multiplex or multiple PCR. Preferably, primers having both comparable base composition and comparable melting temperatures are used. Also preferably, Mg+2 concentration, annealing temperatures, and cycling times of the PCR are optimized prior to choosing the desired set of primer concentrations in accordance with the present invention.
  • PCR techniques applicable to the present invention include inter alia those discussed in PCR PRIMR: A LABORATORY Manual, Dieffenbac, C. W. and Dveksler, G. S., eds., Cold Spring Harbor Laboratory Press (1995).
  • The present application further provides primer sequences, primer concentrations, and experimental conditions useful in the amplification of the coding region of the human p53 gene. Particularly useful primers for amplification of exons of the p53 gene are set forth in Table 1.
    • Table 1
    • p53 Primer Set
  • 20 primers in 1 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, sequences:
    Exon 2: 5′-TCATGCTGCATCCCCACTTTTCCTCTTG-3′
    5′TGGCCTGCCCTTCCAATGGATCCACTCA-3′
    Exon 3: 5′-AATTCATGGGACTGACTTTCTGCTCTTGTC.3′
    5′-TCCAGGTCCCAGCCCAACCCTTGTCC-3′
    Exon 4: 5′-GTCCTCTGACTGCTCTTTTCACCCATCTAC-3′
    5′-GGGATACGGCCAGGCATTGAAGTCTC-3′
    Exon 5: 5′-CTTGTGCCCTGACTTTCAACTCTGTCTC-3′
    5′-TGGGCAACCAGCCCTGTCGTCTCTCCA-3′
    Exon 6: 5′-CCAGGCCTCTGATTCCTCACTGATTGCTC-3′
    5′-GCCACTGACAACCACCCTTAACCCCTC-3′
    Exon 7: 5′-GCCTCATCTTGGGCCTGTGTTATCTCC-3′
    5′-GGCCAGTGTGCAGGGTGGCAAGTGGCTC-3′
    Exon 8: 5′-GTAGGACCTGATTTCCTTACTGCCTTGC-3′
    5′-ATAACTGCACCCTTGGTCTCCTCCACC-3′
    Exon 9: 5′-CACTTTTATCACCTTTCCTTGCCTCTTTCC-3′
    5′-AACTTTCCACTTGATAAGAGGTCCCAAGAC-3′
    Exon 10: 5′-ACTTACTTCTCCCCCTCCTGTGTTGCTGC-3′
    5′-ATGGAATCCTATGGCTTTCCAACCTAGGAAG-3′
    Exon 11: 5′-CATCTCTCCTCCCTGCTTCTGTCTCCTAC-3′
    5′-CTGACGCACACCTATTGCAAGCAAGQGTTC-3′
  • Table 2 shows particularly useful concentrations of the primers set forth in Table 1 for multiplex PCR amplification using the experimental conditions set forth in Table 3.
    TABLE 2
    Primer Concentrations in p53 Primer Set
    Amplicon Length Primer Concs
    Longest 4 368 bp 450.0 nM
    5 272 bp 245.8 nM
    8 241 bp 193.0 nM
    11 231 bp 177.3 nM
    10 210 bp 146.5 nM
    6 204 bp 138.3 nM
    7 175 bp 101.8 nM
    2 164 bp  89.4 nM
    9 146 bp  70.8 nM
    Shortest 3  90 bp  26.9 nM

    Values of X 2

    Typical values of CL 450 nM
  • TABLE 3
    Multiplex PCR
    Start with 250 ng of Template DNA.
    PCR Components for 100 ul PCR in 0.2 ml thin walled tubes:
    Stock
    Conc Final Conc for 1 reaction
    Buffer (No Mg) 10 X 1 X  10.0 ul
    MgCl2 25 mM 2.5 mM  10.0 ul
    dATP
    10 mM 200 uM  2.0 ul
    dCTP
    10 mM 200 uM  2.0 ul
    dGTP
    10 mM 200 uM  2.0 ul
    dTTP
    10 mM 200 uM  2.0 ul
    Taq GOLD 5 U/ul 10 U  2.0 ul
    p53 Primer Set 20 X 1 X  5.0 ul
    Water
    Human genomic
    250 ng
    DNA
    Total 100.0 ul
    Volume
    Final Concentrations in Buffer (No Mg) are 10 mM Tris-HCl (pH 8.3),
    50 mM KCl
    Taq GOLD is AmpliTaq Gold ™ from Perkin Elmer catalog # N808-0243
    PCR Cycles:
    35 Cycles: 94 C. 10 min
    94 C. 30 sec
    60 C. 30 sec
    72 C. 45 sec
    72 C. 10 min
    To visualize amplicons by gel Analysis:
    Visualize PCR products on 4% NuSieve Agarose Gel
    NuSieve ™ Agarose 3:1 is from FMC catalog # 50092
    Load 5 ul of PCR + loading buffer
    Use
    50 bp Ladder (Gibco/BRL catalog # 10416-014) as size marker
    Run gel at 125 Volts for 30 min. to 90 min.
    Expected
    PCR Products: Order in Gel:
    Amplicon Length Amplicon Length
    Exon
    2 164 bp Exon 4 368 bp
    Exon
    3  90 bp Exon 5 272 bp
    Exon
    4 368 bp Exon 8 241 bp
    Exon
    5 272 bp Exon 11 225 bp
    Exon
    6 204 bp Exon 10 210 bp
    Exon 7 175 bp Exon 6 204 bp
    Exon
    8 241 bp Exon 7 175 bp
    Exon 9 146 bp Exon 2 164 bp
    Exon
    10 210 bp Exon 9 146 bp
    Exon
    11 225 bp Exon 3  90 bp
  • Using the methods and reagents provided herein, we achieved multiplex PCR amplification of coding regions shown of the human p53 gene in approximately equimolar amounts. That desirable result was achieved in a single-tube reaction. The achievement of such desirable results with the remarkable convenience of a single tube reaction further illustrates the contribution to the art made by the present invention.
  • The methods and compositions of the present invention are useful in virtually any context in which equimolar yields of various PCR products are desired. Such contexts include without limitation paternity testing, forensic analysis, genetic screening, polymorphism detection, and mutation analyses. The present invention can be used to amplify nucleic acids for all forms of sequence analysis known to those skilled in the art. Sequence analysis techniques includes, for example, dideoxy-sequencing and sequence analysis using high-density nucleic acid arrays: the GeneChip® probe arrays or VLSIPS™ technology of Affymetrix, Inc. High density nucleic acid arrays are discussed for example in Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X. C., Stern, D., Winkler, J., Lockhart, D. J., Morris, M. S., & Fodor, S. P., Science 5287, 610-614 (1996), U.S. Pat. No. 5,445,934, and International Publication No. WO 95/11995 corresponding to PCT Application No. PCT/US94/12305.
  • The p53 gene and its protein product are discussed in Molecular Biology of the Cell, 3rd Edition, Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. D., Garland Publishing (1994) at pages 889 and 1284-1289.
  • It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of any appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Claims (11)

1. A method of performing multiple polymerase chain reactions in a single vessel, comprising:
priming DNA synthesis on a template in a vessel with at least two sets of primers, wherein each of the sets of primers in the vessel is at a predetermined ratio, wherein the ratio is described by:

C A =C L(L A ÷L L)2
wherein CA is the concentration of primers for an amplicon A; wherein CL is the concentration of primer for the longest amplicon; wherein LA is the length of the amplicon A; and wherein LL is the length of the longest amplicon.
2. The method of claim 1 wherein the template is genomic DNA encoding p53.
3. The method of claim 1 wherein the template is a cDNA encoding p53.
4. The method of claim 1 wherein the primers amplify at least 2 exons of p53 selected from the group consisting of exons 2-11.
5. The method of claim 1 wherein the primers amplify at least 4 exons of p53 selected from the group consisting of exons 2-11.
6. The method of claim 1 wherein the primers amplify exons 2-11 of p53.
7. The method of claim 4 wherein the primers are selected from those shown in SEQ ID NO: 1-20.
8. The method of claim 5 wherein the primers are selected from those shown in SEQ ID NO: 1-20.
9. The method of claim 6 wherein the primers are shown in SEQ ID NOS: 1-20.
10. The method of claim 9 wherein the primers are present in the following ratios: exon 2 (89.4): exon 3 (26.9): exon 4 (450): exon 5 (245.8): exon 6 (138.3): exon 7 (101.8): exon 8 (193.0): exon 9 (70.8): exon 10 (146.5): exon 11 (177.3).
11-24. (canceled)
US10/975,361 1997-06-20 2004-10-29 Methods and compositions for multiplex amplification of nucleic acids Abandoned US20050112657A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/975,361 US20050112657A1 (en) 1997-06-20 2004-10-29 Methods and compositions for multiplex amplification of nucleic acids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5040597P 1997-06-20 1997-06-20
US09/099,301 US6333179B1 (en) 1997-06-20 1998-06-18 Methods and compositions for multiplex amplification of nucleic acids
US09/989,441 US6673579B2 (en) 1997-06-20 2001-11-21 Methods and compositions for multiplex amplification of nucleic acids
US10/743,376 US7053206B2 (en) 1997-06-20 2003-12-23 Methods and compositions for multiplex amplification of nucleic acids
US10/975,361 US20050112657A1 (en) 1997-06-20 2004-10-29 Methods and compositions for multiplex amplification of nucleic acids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/743,376 Continuation US7053206B2 (en) 1997-06-20 2003-12-23 Methods and compositions for multiplex amplification of nucleic acids

Publications (1)

Publication Number Publication Date
US20050112657A1 true US20050112657A1 (en) 2005-05-26

Family

ID=21965066

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/099,301 Expired - Lifetime US6333179B1 (en) 1997-06-20 1998-06-18 Methods and compositions for multiplex amplification of nucleic acids
US09/989,441 Expired - Lifetime US6673579B2 (en) 1997-06-20 2001-11-21 Methods and compositions for multiplex amplification of nucleic acids
US10/743,376 Expired - Lifetime US7053206B2 (en) 1997-06-20 2003-12-23 Methods and compositions for multiplex amplification of nucleic acids
US10/975,361 Abandoned US20050112657A1 (en) 1997-06-20 2004-10-29 Methods and compositions for multiplex amplification of nucleic acids

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/099,301 Expired - Lifetime US6333179B1 (en) 1997-06-20 1998-06-18 Methods and compositions for multiplex amplification of nucleic acids
US09/989,441 Expired - Lifetime US6673579B2 (en) 1997-06-20 2001-11-21 Methods and compositions for multiplex amplification of nucleic acids
US10/743,376 Expired - Lifetime US7053206B2 (en) 1997-06-20 2003-12-23 Methods and compositions for multiplex amplification of nucleic acids

Country Status (3)

Country Link
US (4) US6333179B1 (en)
AU (1) AU7980298A (en)
WO (1) WO1998059072A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092904A1 (en) * 2005-10-19 2007-04-26 Biogen Idec Ma Inc. Method for preparing limiting quantities of nucleic acids

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333179B1 (en) * 1997-06-20 2001-12-25 Affymetrix, Inc. Methods and compositions for multiplex amplification of nucleic acids
JP3855492B2 (en) * 1998-10-08 2006-12-13 株式会社日立製作所 Mixed nucleic acid fragment analysis
EP1942196B1 (en) * 2001-12-19 2012-05-30 Brandeis University Late-PCR
US7198897B2 (en) 2001-12-19 2007-04-03 Brandeis University Late-PCR
US7504215B2 (en) 2002-07-12 2009-03-17 Affymetrix, Inc. Nucleic acid labeling methods
AU2003282885A1 (en) * 2002-09-30 2004-04-23 Nimblegen Systems, Inc. Parallel loading of arrays
DE10393431T5 (en) * 2002-10-01 2005-11-17 Nimblegen Systems, Inc., Madison Microarrays with multiple oligonucleotides in single array features
CA2410795A1 (en) * 2002-11-01 2004-05-01 University Of Ottawa A method for the amplification of multiple genetic targets
EP1627075A4 (en) * 2003-05-09 2006-09-20 Univ Tsinghua Methods and compositions for optimizing multiplex pcr primers
EP2316973A1 (en) 2003-06-10 2011-05-04 The Trustees Of Boston University Detection methods for disorders of the lung
US20050191682A1 (en) 2004-02-17 2005-09-01 Affymetrix, Inc. Methods for fragmenting DNA
EP1647600A3 (en) 2004-09-17 2006-06-28 Affymetrix, Inc. (A US Entity) Methods for identifying biological samples by addition of nucleic acid bar-code tags
EP1645640B1 (en) 2004-10-05 2013-08-21 Affymetrix, Inc. Method for detecting chromosomal translocations
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
EP1652580A1 (en) 2004-10-29 2006-05-03 Affymetrix, Inc. High throughput microarray, package assembly and methods of manufacturing arrays
EP1947196A4 (en) * 2005-11-08 2009-09-09 Olympus Corp Method of amplifying multiple nucleic acid sequences for differentiation
EP1953241A1 (en) * 2005-11-29 2008-08-06 Olympus Corporation Method of analyzing change in primary structure of nucleic acid
US7634363B2 (en) 2005-12-07 2009-12-15 Affymetrix, Inc. Methods for high throughput genotyping
US20070231803A1 (en) * 2006-03-31 2007-10-04 Jensen Mark A Multiplex pcr mixtures and kits containing the same
US20070270880A1 (en) * 2006-04-28 2007-11-22 Lindemann Gary S Bone screw revision tools and methods of use
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
US8293684B2 (en) * 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
US8200440B2 (en) 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
WO2009113779A2 (en) 2008-03-11 2009-09-17 국립암센터 Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using snp array
CN104830812B (en) 2009-03-16 2017-09-05 盘古生物制药有限公司 Composition and method comprising the Histidyl-tRNA-synthetase splicing variants with non-classical bioactivity
WO2010120509A2 (en) 2009-03-31 2010-10-21 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US9476868B2 (en) 2009-12-23 2016-10-25 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
JP6066900B2 (en) 2010-04-26 2017-01-25 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of cysteinyl tRNA synthetase
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
AU2011248489B2 (en) 2010-04-28 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
WO2011139854A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
JP5991963B2 (en) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of valyl tRNA synthetase
ES2668207T3 (en) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic and antibody compositions related to fragments of methionyl-tRNA synthetases proteins
ES2623805T3 (en) 2010-05-03 2017-07-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic and antibody compositions related to phenylalanyl-alpha-tRNA synthetase protein fragments
EP2566515B1 (en) 2010-05-03 2017-08-02 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103118694B (en) 2010-06-01 2016-08-03 Atyr医药公司 The discovery for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of lysyl-tRNA synzyme
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
EP2474625B1 (en) * 2011-01-05 2016-11-02 Daniela Kandioler Method for determining the p53 status of a tumour
EP2474624B1 (en) 2011-01-05 2016-08-17 Daniela Kandioler Response prediction in cancer treatment (p53 adapted cancer therapy)
EP3062108B1 (en) 2011-02-24 2019-06-19 Hill's Pet Nutrition, Inc. Methods for diagnosing kidney disorders in a feline
RU2593952C2 (en) 2011-06-15 2016-08-10 Хилл'С Пет Ньютришн, Инк. Compositions and methods for diagnosing and monitoring hyperthyroidism in felines
CN102982222B (en) * 2011-09-02 2016-03-02 司法部司法鉴定科学技术研究所 Obtain the short-cut method without relationship index under sudden change situation
EP2794649B1 (en) 2011-12-19 2016-04-27 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing hyperthyroidism in companion animals
RU2659423C2 (en) 2012-02-16 2018-07-02 ЭйТИР ФАРМА, ИНК. Hystidil-trna-synthetase for treatment of autoimmune and inflammatory diseases
ES2776673T3 (en) 2012-02-27 2020-07-31 Univ North Carolina Chapel Hill Methods and uses for molecular tags
EP3321378B1 (en) 2012-02-27 2021-11-10 Becton, Dickinson and Company Compositions for molecular counting
CN104937111B (en) 2012-11-27 2018-05-11 智利天主教教皇大学 For diagnosing the composition and method of thyroid tumors
AU2016341845B2 (en) 2015-10-18 2022-11-17 Affymetrix, Inc. Multiallelic genotyping of single nucleotide polymorphisms and indels

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314809A (en) * 1991-06-20 1994-05-24 Hoffman-La Roche Inc. Methods for nucleic acid amplification
US5552283A (en) * 1994-07-08 1996-09-03 Visible Genetics Inc. Method, reagents and kit for diagnosis and targeted screening for P53 mutations
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5705365A (en) * 1995-06-07 1998-01-06 Gen-Probe Incorporated Kits for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US6333179B1 (en) * 1997-06-20 2001-12-25 Affymetrix, Inc. Methods and compositions for multiplex amplification of nucleic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
SG68568A1 (en) 1993-07-08 1999-11-16 Johnson & Johnson Clin Diag Method for coamplification of two different nucleic acid sequences using polymerase chain reaction
CA2194697A1 (en) 1994-07-08 1996-01-25 James M. Dunn Method, reagents and kit for diagnosis and targeted screening for p53 mutations
CA2118048C (en) 1994-09-30 2003-04-08 James W. Schumm Multiplex amplification of short tandem repeat loci
EP0873419B1 (en) 1995-06-06 2001-11-21 Beth Israel Deaconess Medical Center Method of and apparatus for diagnostic dna testing
US5882856A (en) 1995-06-07 1999-03-16 Genzyme Corporation Universal primer sequence for multiplex DNA amplification

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5314809A (en) * 1991-06-20 1994-05-24 Hoffman-La Roche Inc. Methods for nucleic acid amplification
US5552283A (en) * 1994-07-08 1996-09-03 Visible Genetics Inc. Method, reagents and kit for diagnosis and targeted screening for P53 mutations
US5705365A (en) * 1995-06-07 1998-01-06 Gen-Probe Incorporated Kits for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US6333179B1 (en) * 1997-06-20 2001-12-25 Affymetrix, Inc. Methods and compositions for multiplex amplification of nucleic acids
US6673579B2 (en) * 1997-06-20 2004-01-06 Affymetrix, Inc. Methods and compositions for multiplex amplification of nucleic acids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092904A1 (en) * 2005-10-19 2007-04-26 Biogen Idec Ma Inc. Method for preparing limiting quantities of nucleic acids

Also Published As

Publication number Publication date
US6673579B2 (en) 2004-01-06
WO1998059072A1 (en) 1998-12-30
US6333179B1 (en) 2001-12-25
AU7980298A (en) 1999-01-04
US20040126806A1 (en) 2004-07-01
US7053206B2 (en) 2006-05-30
US20020058281A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
US6673579B2 (en) Methods and compositions for multiplex amplification of nucleic acids
US5843660A (en) Multiplex amplification of short tandem repeat loci
Wu et al. Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia.
EP0731177B1 (en) Method of characterising genomic DNA
US6221598B1 (en) Multiplex amplification of short tandem repeat loci
JP3693352B2 (en) Methods for detecting genetic polymorphisms and monitoring allelic expression using probe arrays
EP2271777B1 (en) Substances and methods for a dna based profiling assay
EP1248853A2 (en) Liquid array technology
JP2002530121A (en) Multiple amplification of short tandem repeat loci
JP2007525998A (en) Detection of STRP such as fragile X syndrome
EP0777747A1 (en) Nucleotide sequencing method
JP4317953B2 (en) DNA sequence determination method
US5910413A (en) Method and kit for amplification, sequencing and typing of classical HLA class I genes
US20080076130A1 (en) Molecular haplotyping of genomic dna
Umetsu et al. Multiplex amplified product‐length polymorphism analysis for rapid detection of human mitochondrial DNA variations
Tranah et al. Multiple displacement amplification prior to single nucleotide polymorphism genotyping in epidemiologic studies
Martin et al. Characterization of 12 microsatellite loci of the human MHC in a panel of reference cell lines
JP4926079B2 (en) Breast cancer-related polynucleotide containing single nucleotide polymorphism, microarray and diagnostic kit containing the same, and method for diagnosing breast cancer using the same
Steven et al. Genetic markers in blue crabs (Callinectes sapidus) I: Isolation and characterization of microsatellite markers
Lo et al. Detection of chimaerism after bone marrow transplantation using the double amplification refractory mutation system
van der Slik et al. Subtyping for TNFa microsatellite sequence variation
WO1999050450A1 (en) Polymorphism iii: linkage of atopy to a locus on chromosome 13
WO1999050451A1 (en) Polymorphism i: linkage of asthma to a locus on chromosome 2
EP1066412A1 (en) Polymorphism ii : linkage of asthma to a locus on chromosome 4
Anker Schumm et al.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION